Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maxime Brunet

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Bulletin Du Cancer|July 1, 2022
[New drug approval: Adjuvant Pembrolizumab in clear-cell renal-cell carcinoma at high risk for recurrence after nephrectomy]Maxime Brunet, Gabriel G Malouf
Frontiers in Oncology|November 30, 2019
Enabling Precision Medicine for Rare Head and Neck Tumors: The Example of BRAF/MEK Targeting in Patients With Metastatic AmeloblastomaMaxime Brunet, Emmanuel Khalifa, Antoine Italiano
Physical Review Letters|April 14, 2020
Shortcut to Geostrophy in Wave-Driven Rotating Turbulence: The Quartetic InstabilityMaxime Brunet, Basile Gallet, Pierre-Philippe Cortet
Physical Review Letters|January 8, 2021
Quantitative Experimental Observation of Weak Inertial-Wave TurbulenceEduardo Monsalve, Maxime Brunet, Basile Gallet, et al.
Tumori|October 25, 2019
From palliative to curative intent: PET/CT findings in the light of breast cancer intrinsic subgroupMaxime Brunet, Anne-Laure Cazeau, Houda Ben Rejeb, et al.
Med (New York, N.Y.)|January 11, 2025
Tertiary lymphoid structures and cancer immunotherapy: From bench to bedsideFlorent Peyraud, Jean-Philippe Guegan, Lucile Vanhersecke, et al.
Clinical and Experimental Medicine|February 16, 2026
Prognostic significance of tumor fraction in advanced sarcoma: highlighting a novel circulating biomarkerSofiane Taleb, Maxime Brunet, Laila Belcaid, et al.
Journal for Immunotherapy of Cancer|May 26, 2022
Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodiesMathieu Larroquette, Jean-Philippe Guegan, Benjamin Besse, et al.
Cell Reports. Medicine|February 5, 2025
Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structuresFlorent Peyraud, Jean-Philippe Guégan, Christophe Rey, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|February 21, 2023
Standardized Pathology Screening of Mature Tertiary Lymphoid Structures in CancersLucile Vanhersecke, Antoine Bougouin, Amandine Crombé, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Bulletin Du Cancer|July 1, 2022
[New drug approval: Adjuvant Pembrolizumab in clear-cell renal-cell carcinoma at high risk for recurrence after nephrectomy]Maxime Brunet, Gabriel G Malouf
Frontiers in Oncology|November 30, 2019
Enabling Precision Medicine for Rare Head and Neck Tumors: The Example of BRAF/MEK Targeting in Patients With Metastatic AmeloblastomaMaxime Brunet, Emmanuel Khalifa, Antoine Italiano
Physical Review Letters|April 14, 2020
Shortcut to Geostrophy in Wave-Driven Rotating Turbulence: The Quartetic InstabilityMaxime Brunet, Basile Gallet, Pierre-Philippe Cortet
Physical Review Letters|January 8, 2021
Quantitative Experimental Observation of Weak Inertial-Wave TurbulenceEduardo Monsalve, Maxime Brunet, Basile Gallet, et al.
Tumori|October 25, 2019
From palliative to curative intent: PET/CT findings in the light of breast cancer intrinsic subgroupMaxime Brunet, Anne-Laure Cazeau, Houda Ben Rejeb, et al.
Med (New York, N.Y.)|January 11, 2025
Tertiary lymphoid structures and cancer immunotherapy: From bench to bedsideFlorent Peyraud, Jean-Philippe Guegan, Lucile Vanhersecke, et al.
Clinical and Experimental Medicine|February 16, 2026
Prognostic significance of tumor fraction in advanced sarcoma: highlighting a novel circulating biomarkerSofiane Taleb, Maxime Brunet, Laila Belcaid, et al.
Journal for Immunotherapy of Cancer|May 26, 2022
Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodiesMathieu Larroquette, Jean-Philippe Guegan, Benjamin Besse, et al.
Cell Reports. Medicine|February 5, 2025
Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structuresFlorent Peyraud, Jean-Philippe Guégan, Christophe Rey, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|February 21, 2023
Standardized Pathology Screening of Mature Tertiary Lymphoid Structures in CancersLucile Vanhersecke, Antoine Bougouin, Amandine Crombé, et al.
Pageof 2